The company's past year sales total was 40.56 Million. The Mean and Low price Targets are $2.6 and $1.2, respectively. It has gained $0.23 (-15.23%) since hitting a 52-week high price of $1.51. However a year ago for the same quarter the company has reported $0.77 earnings per share.
Protalix Biotherapeutics Inc (NYSEMKT:PLX)'s mean EPS estimate was $-0.08 for the quarter ended on 3/2016, while it reported EPS of $-0.09 on 5/9/2016, missing the analysts' consensus estimate by -0.01 with surprise factor of -12.50%.
Whereas they predicted High and Low Earnings Estimate as $-0.09 and $-0.13 respectively. The company's outstanding shares are 315.97 Million. The stock has a Return on Assets of 0 percent, Return on Investment of 0 percent and a Return on Equity of 0 percent. The analysts believe that the company stock price could grow as high as $4.
On Wednesday, Protalix Biotherapeutics Inc (NYSEMKT:PLX) stock opened its trade at $1.40 and after floating in a range of $1.10 to $1.45, settled at $1.28. They now have a Dollars 3.4 price target on the stock.
Price Target is an important factor while doing analysis of a stock. The short ratio in the company's stock is documented at 1.2 and the short float is around of 5.37%. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell. The company has a Low Price Target of $13 and the Mean Target of $20, according to the Brokers. While the actual EPS the company reported in the same quarter previous year was 0.77/share.
Considering the performance, Protalix BioTherapeutics, Inc. While it's Return on Investment (ROI) value is 0%.
11/12/2014 - Protalix BioTherapeutics, Inc. had its "buy" rating reiterated by analysts at R. F. Lafferty. (PLX) reported Q2 earnings loss of -$0.11, missing consensus estimates of -$0.08. The company's 50 day moving average price is $0.97 and its 200 day moving average price is $0.61. Its forecasts over growth are -162.30% during current year while analysts' growth estimation for the next year is 28.90%. The stock's next day closing price was $0.44 with the gain of 7.32% in its share price.
Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) has a market capitalization of 203.9 Million. The stock's quarterly performance indicates a Positive momentum of 380 percent, whereas its last one month trend is Optimistic with 42.57 percent. Year to Date performance value (YTD perf) value is 217.78%. The higher end of the revenue estimate is $3.45 Billion and the lower end is $2.63 Billion. Adding one more ration to find detail valuation of security, price to earnings growth ration that stands at 0.12.